165 related articles for article (PubMed ID: 32295687)
21. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
22. The solubility-permeability interplay and oral drug formulation design: Two heads are better than one.
Dahan A; Beig A; Lindley D; Miller JM
Adv Drug Deliv Rev; 2016 Jun; 101():99-107. PubMed ID: 27129443
[TBL] [Abstract][Full Text] [Related]
23. The developability classification system: application of biopharmaceutics concepts to formulation development.
Butler JM; Dressman JB
J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
[TBL] [Abstract][Full Text] [Related]
24. Use of the Biopharmaceutical Classification System in early drug development.
Ku MS
AAPS J; 2008; 10(1):208-12. PubMed ID: 18446521
[TBL] [Abstract][Full Text] [Related]
25. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
Zhang T; Heimbach T; Lin W; Zhang J; He H
J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
[TBL] [Abstract][Full Text] [Related]
26. Computational models to assign biopharmaceutics drug disposition classification from molecular structure.
Khandelwal A; Bahadduri PM; Chang C; Polli JE; Swaan PW; Ekins S
Pharm Res; 2007 Dec; 24(12):2249-62. PubMed ID: 17846869
[TBL] [Abstract][Full Text] [Related]
27. Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules.
Dave VS; Gupta D; Yu M; Nguyen P; Varghese Gupta S
Drug Dev Ind Pharm; 2017 Feb; 43(2):177-189. PubMed ID: 27998192
[TBL] [Abstract][Full Text] [Related]
28. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
29. Biopharmaceutic classification of drugs revisited.
Daousani C; Macheras P
Eur J Pharm Sci; 2016 Dec; 95():82-87. PubMed ID: 27496048
[TBL] [Abstract][Full Text] [Related]
30. Application of data mining approach to identify drug subclasses based on solubility and permeability.
Gatarić B; Parojčić J
Biopharm Drug Dispos; 2019 Feb; 40(2):51-61. PubMed ID: 30635908
[TBL] [Abstract][Full Text] [Related]
31. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
32. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research.
Varma MV; Khandavilli S; Ashokraj Y; Jain A; Dhanikula A; Sood A; Thomas NS; Pillai O; Sharma P; Gandhi R; Agrawal S; Nair V; Panchagnula R
Curr Drug Metab; 2004 Oct; 5(5):375-88. PubMed ID: 15544432
[TBL] [Abstract][Full Text] [Related]
33. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation.
Zur M; Hanson AS; Dahan A
Eur J Pharm Sci; 2014 Sep; 61():11-7. PubMed ID: 24262076
[TBL] [Abstract][Full Text] [Related]
34. Establishment of modified biopharmaceutics classification system absorption model for oral Traditional Chinese Medicine (Sanye Tablet).
Li H; Cao X; Liu Y; Liu T; Wang M; Ren X; Dou Z
J Ethnopharmacol; 2019 Nov; 244():112148. PubMed ID: 31400507
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
36. Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.
Gandhi SV; Rodriguez W; Khan M; Polli JE
AAPS PharmSciTech; 2014 Jun; 15(3):601-11. PubMed ID: 24557773
[TBL] [Abstract][Full Text] [Related]
37. Reconciling Human-Canine Differences in Oral Bioavailability: Looking beyond the Biopharmaceutics Classification System.
Martinez MN; El-Kattan A; Awji E; Papich M
AAPS J; 2019 Aug; 21(5):99. PubMed ID: 31396733
[TBL] [Abstract][Full Text] [Related]
38. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.
Parr A; Hidalgo IJ; Bode C; Brown W; Yazdanian M; Gonzalez MA; Sagawa K; Miller K; Jiang W; Stippler ES
Pharm Res; 2016 Jan; 33(1):167-76. PubMed ID: 26286187
[TBL] [Abstract][Full Text] [Related]
40. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Lindenberg M; Kopp S; Dressman JB
Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
